Log In
Print
BCIQ
Print
Print this Print this
 

actoxumab/bezlotoxumab (MDX-066/MDX-1388) (MK-3415A)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionCombination of two human mAbs targeting against Clostridium difficile toxins A and B
Molecular Target Clostridium difficile toxin A (TcdA) ; Clostridium difficile toxin B (TcdB)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationClostridium
Indication DetailsTreat Clostridium difficile infection (CDI)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today